A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (JS203-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.

Trial Details

NCT ID
NCT07808827
Phase
PHASE3
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • JS203 in combination with gemcitabine and oxaliplatin
  • Rituximab in combination with gemcitabine and oxaliplatin
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients must meet all of the following inclusion criteria to be enrolled:
  • Age range: 18 to 75 years old (inclusive), both male and female are acceptable
  • ECOG: 0-1;
  • One of the confirmed histologies below with CD20-positivity:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →